Recce Pharmaceuticals Secures Vietnamese Patent for Novel Anti-Infectives
Recce Pharmaceuticals has expanded its intellectual property footprint with a key patent granted in Vietnam for its RECCE® anti-infective drugs, reinforcing its presence in a critical Southeast Asian market grappling with high antibiotic resistance.
- Vietnamese patent granted for RECCE® 327 and 529
- Patent covers treatment methods and multiple administration routes
- Vietnam faces severe antibiotic resistance challenges
- Vietnamese pharmaceutical market valued at USD 7–8 billion
- Recce’s global patent portfolio now spans major markets
Vietnam Patent Boosts Recce’s IP in Southeast Asia
Recce Pharmaceuticals Limited (ASX:RCE) has secured a Family 4 patent in Vietnam for its flagship synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529), extending protection until 2041. The patent covers the preparation processes and therapeutic uses of these compounds against a broad spectrum of infections, including bacterial, viral, and particularly drug-resistant strains.
The granted patent also validates multiple administration methods, ranging from oral and inhalation to injectable forms, as well as topical applications like gels and foams. This comprehensive coverage aligns with Recce’s strategy to safeguard its platform technology in strategically important markets.
Vietnam’s Growing Pharmaceutical Market and Resistance Crisis
Vietnam represents one of Southeast Asia’s fastest-growing pharmaceutical sectors, valued between USD 7 and 8 billion and forecast to exceed USD 10 to 16 billion by 2026. The country’s acute antimicrobial resistance problem adds urgency to the need for novel treatments. Studies cited by Recce reveal alarmingly high resistance rates, 71% to Penicillin and 92% to Erythromycin, with multi-drug resistance prevalent in common hospital pathogens such as Escherichia coli and Acinetobacter baumannii.
This environment underscores the commercial and clinical significance of Recce’s anti-infectives, which are designed to overcome mechanisms that render many existing antibiotics ineffective.
Global Patent Network Supports Commercial Ambitions
The Vietnam patent is Recce’s eighth Family 4 patent, complementing protection already secured in major pharmaceutical markets including Australia, Canada, China, and Brazil. The company has further Patent Cooperation Treaty submissions under review, reflecting a global approach to intellectual property management.
Recce’s CEO James Graham emphasised that expanding patent coverage in Southeast Asia is a key milestone for the company’s commercialisation plans, especially as antibiotic resistance remains a pressing global health threat.
Pipeline and Regulatory Recognition
Recce’s pipeline includes three patented synthetic polymers: R327 for intravenous and topical use against serious bacterial infections, R435 as an oral therapy for bacterial infections, and R529 targeting viral infections. The World Health Organization has recognised these candidates on its list of antibacterial products in clinical development for priority pathogens. Additionally, R327 holds FDA Fast Track and Qualified Infectious Disease Product status, granting it market exclusivity incentives.
With clinical trials advancing and an automated manufacturing facility in place, Recce is positioned to address unmet medical needs in antibiotic-resistant infections worldwide.
Bottom Line?
Vietnam’s patent grant solidifies Recce’s foothold in a critical market confronting antibiotic resistance, but translating IP strength into commercial success will hinge on clinical progress and regulatory approvals.
Questions in the middle?
- How will Recce prioritise market entry and partnerships in Vietnam and Southeast Asia?
- What are the timelines for regulatory approvals and commercial launches in this region?
- Will ongoing clinical trials confirm efficacy against multidrug-resistant infections prevalent in Vietnam?
